Synthesis and HPLC-purification of [77Br]TMC125-R165335 (etravirine), a new anti-HIV drug of the DAPY-NNRTI class
暂无分享,去创建一个
G. Slegers | K. Peremans | L. Baert | F. Dumont | C. Burvenich | B. Spiegeleer | P. Wigerinck | L. V. Vooren | J. Rosier
[1] Rudi Pauwels,et al. New non-nucleoside reverse transcriptase inhibitors (NNRTIs) in development for the treatment of HIV infections. , 2004, Current opinion in pharmacology.
[2] Erik De Clercq,et al. HIV-chemotherapy and -prophylaxis: new drugs, leads and approaches. , 2004 .
[3] R. Gulick,et al. New antiretroviral agents for the treatment of HIV infection , 2004, Current HIV/AIDS reports.
[4] H. M. Vinkers,et al. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. , 2004, Journal of medicinal chemistry.
[5] B. Haslinger,et al. TMC-125 Tibotec. , 2004, Current opinion in investigational drugs.
[6] B. Gazzard,et al. An open-label assessment of TMC 125—a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance , 2003, AIDS.
[7] G. Weverling,et al. TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen , 2003, AIDS.
[8] R. Pauwels,et al. Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues. , 2001, Bioorganic & medicinal chemistry letters.
[9] Erik De Clercq,et al. Non‐Nucleoside Reverse Transcriptase Inhibitors (NNRTIs): Past, Present, and Future , 2004, Chemistry & biodiversity.
[10] G. Slegers,et al. Production and Purification of 77Br Suitable for Labeling Monoclonal Antibodies Used in Tumor Imaging , 1994 .
[11] A. Nunn,et al. Target materials for the cyclotron production of carrier-free 77Br , 1975 .